- Home
- OXLC vs NAMS Comparison
OXLC vs NAMS Comparison
Compare OXLC & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OXLC
- NAMS
- Stock Information
- Founded
- OXLC 2010
- NAMS 2019
- Country
- OXLC United States
- NAMS Netherlands
- Employees
- OXLC N/A
- NAMS N/A
- Industry
- OXLC Investment Managers
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- OXLC Finance
- NAMS Health Care
- Exchange
- OXLC Nasdaq
- NAMS Nasdaq
- Market Cap
- OXLC 2.1B
- NAMS 2.5B
- IPO Year
- OXLC N/A
- NAMS N/A
- Fundamental
- Price
- OXLC $4.08
- NAMS $17.96
- Analyst Decision
- OXLC Strong Buy
- NAMS Strong Buy
- Analyst Count
- OXLC 1
- NAMS 8
- Target Price
- OXLC $6.00
- NAMS $42.88
- AVG Volume (30 Days)
- OXLC 1.9M
- NAMS 893.6K
- Earning Date
- OXLC 11-01-2023
- NAMS 08-06-2025
- Dividend Yield
- OXLC 18.86%
- NAMS N/A
- EPS Growth
- OXLC N/A
- NAMS N/A
- EPS
- OXLC 1.20
- NAMS N/A
- Revenue
- OXLC $130,145,365.00
- NAMS $47,140,000.00
- Revenue This Year
- OXLC $136.15
- NAMS N/A
- Revenue Next Year
- OXLC $5.51
- NAMS N/A
- P/E Ratio
- OXLC $4.24
- NAMS N/A
- Revenue Growth
- OXLC N/A
- NAMS 586.97
- 52 Week Low
- OXLC $4.41
- NAMS $14.06
- 52 Week High
- OXLC $5.70
- NAMS $27.29
- Technical
- Relative Strength Index (RSI)
- OXLC 24.35
- NAMS 42.30
- Support Level
- OXLC $4.05
- NAMS $20.06
- Resistance Level
- OXLC $4.54
- NAMS $21.91
- Average True Range (ATR)
- OXLC 0.08
- NAMS 1.41
- MACD
- OXLC -0.04
- NAMS -0.20
- Stochastic Oscillator
- OXLC 6.12
- NAMS 4.45
About OXLC Oxford Lane Capital Corp.
Oxford Lane Capital Corp is a non-diversified closed-end management investment company. The fund's investment objective is to maximize its portfolio's risk-adjusted total return over its investment horizon. Its current focus is to seek that return by investing in equity and junior tranches of CLO(collateralized loan obligation) vehicles, which are collateralized by a diverse portfolio of senior loans, and which generally have little to no exposure to real estate loans, mortgage loans or pools of consumer-based debt, such as credit card receivables or auto loans. Its investment plan also includes investing in warehouse facilities, which are financing structures intended to aggregate senior loans that may be used to form the basis of a CLO vehicle.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.